Takeda Pharmaceutical Co Ltd

TAK NYSE SEC CIK 1395064
Follow Takeda Pharmaceutical Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 JPY · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income10 fiscal years
  • Revenue
  • Net income
¥0¥2T¥4T¥6TFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25¥4.58T¥107.9B
FY24¥4.26T¥144.1B
FY23¥4.03T¥317B
FY22¥3.57T¥230.1B
FY21¥3.2T¥376B
FY20¥3.29T¥44.2B
FY19¥2.1T¥135.2B
FY18¥1.77T¥186.9B
FY17¥1.73T¥114.9B
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%20%40%60%80%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2565.5%7.5%2.4%
FY2466.5%5%3.4%
FY2369.1%12.2%7.9%
FY2269%12.9%6.4%
FY2168.9%15.9%11.8%
FY2066.9%3.1%1.3%
FY1968.9%11.3%6.4%
FY1872%13.7%10.6%
FY1767.7%9%6.6%
FY16---
Free cash flowOperating cash flow minus capital expenditure
¥0¥250B¥500B¥750B¥1TFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25¥856.4B
FY24¥540.9B
FY23¥836.5B
FY22¥999.9B
FY21¥899.7B
FY20¥542.7B
FY19¥250.8B
FY18¥310.8B
FY17¥199.7B
FY16-
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
¥0¥100B¥200B¥300B¥400BFY17FY19FY21FY23FY25
Show the numbers
YearDividendsBuybacks
FY25¥302.5B¥51.9B
FY24¥287.2B¥2.3B
FY23¥279.4B¥26.9B
FY22¥283.7B¥77.5B
FY21¥283.4B¥2.1B
FY20¥282.6B¥3.7B
FY19¥143B¥1.2B
FY18¥141.9B¥18.8B
FY17¥141.7B¥23.1B
FY16--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Takeda Pharmaceutical
  • Healthcare median
−100%−75%−50%−25%0%25%FY17FY19FY21FY23FY25
Show the numbers
YearTakeda PharmaceuticalHealthcare median
FY252.4%−30.6%
FY243.4%−47%
FY237.9%−58%
FY226.4%−80.4%
FY2111.8%−71.9%
FY201.3%−62.2%
FY196.4%−46.3%
FY1810.6%−49.6%
FY176.6%−45.9%
FY16-−36%